652 XPA Promotes Autophagy to Facilitate Cisplatin Resistance in Melanoma Cells Through the Activation of PARP1
R. Ge,L. Liu,W. Dai,W. Zhang,Y. Yang,H. Wang,Q. Shi,S. Guo,X. Yi,G. Wang,T. Gao,Q. Luan,C. Li
DOI: https://doi.org/10.1016/j.jid.2016.02.693
IF: 7.59
2016-01-01
Journal of Investigative Dermatology
Abstract:Xeroderma pigmentosum group A (XPA), a key protein in nucleotide excision repair (NER) pathway, has been shown to promote the resistance of tumor cells to chemotherapeutic drugs by facilitating the DNA repair process. However, the role of XPA in the resistance to platinum-based drugs like cisplatin in melanoma is largely unknown. In this study, we initially found that XPA was expressed at higher levels in cisplatin-resistant melanoma cells than that in cisplatin-sensitive ones. Furthermore, the knockdown of XPA not only increased cellular apoptosis but also inhibited cisplatin-induced autophagy, which rendered the melanoma cells more sensitive to cisplatin. Moreover, we discovered that the increased XPA in resistant melanoma cells promoted poly (ADP-ribose) polymerase 1 (PARP1) activation, and the inhibition of PARP1 could attenuate the cisplatin-induced autophagy. At last, we proved that the inhibition on PARP1 as well as the autopagy process made resistant melanoma cells more susceptible to cisplatin treatment. In conclusion, our study demonstrates that XPA can promote cell-protective autophagy in a DNA repair-independent manner by enhancing the activation of PARP1 in melanoma cells resistant to cisplatin, and the XPA-PARP1-mediated autophagy process can be targeted to overcome cisplatin resistance in melanoma chemotherapy.